Physician profile
Mark Grand
NPI 1487696514
$635.14
in general payments reported to CMS, 2019-2025
12 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $132 · 2023: $138 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160.90 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $106.11 | 2021 | |
| Daiichi Sankyo INC. | $68.26 | 2022-2023 | Injectafer, Enhertu |
| Alexion Pharmaceuticals, INC. | $62.95 | 2021-2022 | |
| Genzyme Corporation | $58.69 | 2023 | |
| Adc Therapeutics America, INC. | $47.48 | 2022-2023 | |
| Kite Pharma, INC. | $31.96 | 2021 | |
| Janssen Biotech, INC. | $31.32 | 2022 | |
| Exelixis INC. | $22.17 | 2021 | |
| Astellas Pharma US INC | $17.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.27 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Grand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.